Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
IMV Inc. IMV
$0.82
На 05:31, 10 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
9632791.00000000
-
week52high
11.00
-
week52low
0.48
-
Revenue
0
-
P/E TTM
-18
-
Beta
1.42434500
-
EPS
-4.55000000
-
Last Dividend
0.00000000
-
Next Earnings Date
11 мая 2023 г. в 12:30
Описание компании
IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and microsatellite instability high tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Cantor Fitzgerald | Overweight | 22 сент 2021 г. | |
| Wells Fargo | Overweight | Equal-Weight | 18 мая 2020 г. |
| H.C. Wainwright | Buy | Buy | 15 мая 2020 г. |
| B. Riley FBR | Neutral | Buy | 01 апр 2020 г. |
| B. Riley FBR | Buy | 28 февр 2020 г. | |
| HC Wainwright & Co. | Buy | Buy | 15 мая 2020 г. |
| B. Riley Securities | Neutral | Buy | 01 апр 2020 г. |
| HC Wainwright & Co. | Buy | Buy | 21 дек 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
IMV Inc. (IMV) Q4 2022 Earnings Call Transcript
Seeking Alpha
16 мар 2023 г. в 11:02
IMV Inc. (NASDAQ:IMV ) Q4 2022 Earnings Conference Call March 16, 2023 8:00 AM ET Company Participants Andrew Hall - Chief Executive Officer Brittany Davison - Chief Accounting Officer Jeremy Graff - Chief Scientific Officer Conference Call Participants Joe Pantginis - H.C. Wainwright Brandon Folkes - Cantor Fitzgerald Doug Loe - Leede Jones Gable Operator Good day and thank you for standing by.
IMV Inc. to Announce Fourth Quarter and Fiscal Year 2022 Results and Host a Conference Call and Webcast on March 16, 2023
Business Wire
09 мар 2023 г. в 07:05
DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $IMV #CancerVaccine--IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies, based on its novel DPX platform, to treat solid and hematologic cancers, today announced that it will hold a conference call and webcast on Thursday, March 16, 2023, at 8:00 a.m. ET to discuss the company's 2022 fourth quarter and fiscal year-end financial and operational results.
IMV, Inc. (IMV) Q3 2022 Earnings Call Transcript
Seeking Alpha
12 ноя 2022 г. в 09:25
IMV, Inc. (NASDAQ:IMV ) Q3 2022 Earnings Conference Call November 11, 2022 8:00 AM ET Company Participants Brittany Davison - Chief Accounting Officer Andrew Hall - Chief Executive Officer Jeremy Graff - Chief Scientific Officer Conference Call Participants Brandon Folkes - Cantor Fitzgerald Joseph Pantginis - H.C. Wainwright & Co. Paul Stewardson - IA Capital Markets Operator Good day and thank you for standing by.
IMV Inc. to Announce Third Quarter 2022 Results and Host a Conference Call and Webcast on November 11, 2022
Business Wire
08 ноя 2022 г. в 07:05
DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.
IMV Inc. to Present at Two Investor Conferences in September
Business Wire
01 сент 2022 г. в 07:05
DARTMOUTH, Nova Scotia, & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $IMV #DeliveryPlatform--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today announced that members of IMV's executive management team will be presenting at two investor conferences in September. Please find additional details on the conferences below. H.C. Wainwright 24th Annual Global Investment Conference, New York City